US 12,252,718 B2
DNA modifying enzymes and active fragments and variants thereof and methods of use
Tyson D. Bowen, Morrisville, NC (US); Alexandra Briner Crawley, Cary, NC (US); and Tedd D. Elich, Durham, NC (US)
Assigned to Life Edit Therapeutics, Inc., Durham, NC (US)
Filed by LifeEDIT Therapeutics, Inc., Durham, NC (US)
Filed on Apr. 10, 2024, as Appl. No. 18/631,568.
Application 18/631,568 is a division of application No. 17/929,162, filed on Sep. 1, 2022, granted, now 11,981,940.
Application 17/929,162 is a continuation of application No. 17/851,880, filed on Jun. 28, 2022.
Application 17/851,880 is a continuation of application No. PCT/US2021/049853, filed on Sep. 10, 2021.
Claims priority of provisional application 63/146,840, filed on Feb. 8, 2021.
Claims priority of provisional application 63/077,089, filed on Sep. 11, 2020.
Prior Publication US 2024/0360428 A1, Oct. 31, 2024
Int. Cl. C12N 9/22 (2006.01); C12N 15/63 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 15/63 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 20 Claims
 
1. A fusion protein comprising a Type II CRISPR-Cas protein nickase and a deaminase, wherein said deaminase comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 405 and has adenine deaminase activity, and wherein said nickase
(a) is a Cas9 nickase; or
(b) comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NO: 42, 52, 53, 55-59, 61, 397, or 398.